AI-generated summary
This review summarizes in vitro, animal, and clinical studies of red and near-infrared photobiomodulation for age-related disorders, including metabolic, neurodegenerative, cardiovascular, and macular conditions. The authors report beneficial effects in several areas and describe photobiomodulation as promising, while noting it still lacks standardized protocols and that wavelengths, doses and frequencies vary across studies.
- Who or what was studied
- Individuals with age-related disorders, and in vitro, animal and clinical study models
- Limits stated in the abstract
- The abstract states that photobiomodulation lacks standardized treatment protocols and that wavelengths, dosage and frequency differ among studies.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Red light therapy, Age-related macular degeneration, Adenosine triphosphate, Cytochrome c oxidase, Oral mucositis, Reactive oxygen species, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.